ERV41 Antibody

What is ERV41 and what is its primary cellular function?

ERV41 is a conserved integral membrane protein that forms a complex with ERV46. This complex primarily functions as a retrograde receptor for the retrieval of non-HDEL-bearing endoplasmic reticulum (ER) resident proteins that escape to the Golgi apparatus. Unlike the KDEL receptor system, which recognizes the KDEL/HDEL motif, the ERV41-ERV46 complex appears to recognize a distinct class of ER resident proteins through a novel interaction motif . The complex predominantly localizes to the ER-Golgi intermediate compartment and early Golgi compartments, similar to KDEL receptors, suggesting its involvement in protein quality control mechanisms within the early secretory pathway .

How does the ERV41-ERV46 complex differ from the KDEL receptor?

The ERV41-ERV46 complex represents a retrieval mechanism distinct from the KDEL receptor system in several key aspects. While KDEL receptors are seven-transmembrane domain proteins that recognize the C-terminal KDEL/HDEL sequence, the ERV41-ERV46 complex has most of its mass facing the ER lumen and retrieves soluble ER-luminal proteins that lack the KDEL/HDEL signals . Structural studies of the ERV41 luminal domain have revealed an unusual β-sandwich arrangement with a prominent negative electrostatic surface patch, suggesting that this receptor recognizes cargo proteins through a unique binding mechanism . This distinction implies that cells employ multiple independent mechanisms to ensure proper localization of different classes of ER resident proteins.

What happens when ERV41 is deleted in yeast cells?

When ERV41 is deleted (erv41Δ), multiple ER resident proteins are mistargeted, resulting in their significant reduction at steady-state levels. Quantitative proteomic analysis using SILAC (Stable Isotope Labeling by Amino acids in Cell culture) has identified approximately 20 proteins that are significantly reduced in both erv41Δ and erv46Δ strains . Notable examples include:

• Glucosidase I (Gls1): reduced by approximately 75% based on log2 ratios

• Peptidyl-prolyl cis-trans isomerase (Fpr2): reduced by approximately 94%

• ER DnaJ protein (Jem1): reduced by approximately 49%

• Vacuolar protein sorting protein (Vps62): reduced by approximately 44%

In addition to reduced cellular levels, these proteins are often mistargeted to the vacuole for degradation or secreted to the extracellular medium, demonstrating the essential role of ERV41 in maintaining proper ER protein localization .

What molecular mechanisms control the trafficking of the ERV41-ERV46 complex between ER and Golgi?

The trafficking of the ERV41-ERV46 complex between organelles is controlled by specific amino acid residues in the C-terminal regions of both proteins. Particularly critical are isoleucine 349 and leucine 350 at positions -4 and -3 from the C-terminus of ERV41 . When these residues are mutated to alanine (I349A and L350A), the packaging of the ERV41-ERV46 complex into COPII vesicles is completely abolished, causing the complex to accumulate in ER membranes despite being expressed at near wild-type levels .

This suggests that these C-terminal residues function as an ER export signal recognized by the COPII coat complex. The interaction likely occurs through the Sec24 subunit, which recognizes diverse export signals in membrane proteins. For anterograde transport, the complex must be properly assembled, as mutations affecting complex formation also disrupt trafficking. For retrograde transport from Golgi to ER, the complex recognizes specific cargo proteins lacking the HDEL/KDEL motif through its luminal domain .

How does the ERV41-ERV46 complex recognize its cargo proteins?

The recognition mechanism of the ERV41-ERV46 complex for its cargo proteins involves specific structural features in the luminal domain of ERV41. Structural studies have identified an unusual β-sandwich arrangement in the ERV41 luminal domain with a prominent negative electrostatic surface patch that is thought to mediate protein-protein interactions . This suggests that the complex recognizes a specific motif or structural element in its cargo proteins that is distinct from the KDEL/HDEL signal.

The 118-amino acid protein Fpr2 has proven useful as a model cargo for studying this recognition process. Current research efforts are focused on defining the specific sorting motif within Fpr2 that is recognized by the ERV41-ERV46 complex . Identification of this sorting signal will allow bioinformatic searches for other potential cargoes of the ERV41-ERV46 retrieval system and may reveal parallels to pathogenic factors that exploit retrograde trafficking pathways to access the ER.

What is the relationship between ERV41-ERV46 complex function and the unfolded protein response?

Interestingly, unlike strains with deletions of other anterograde cargo receptors, erv41Δ and erv46Δ strains do not display an activated unfolded protein response (UPR) . This suggests that the primary function of the ERV41-ERV46 complex is in retrograde trafficking rather than anterograde transport of proteins critical for ER homeostasis.

What are the best methods for detecting ERV41 protein in experimental samples?

For detecting ERV41 protein in experimental samples, immunoblotting with specific antibodies is the most widely used method. When working with native ERV41, researchers typically use polyclonal or monoclonal antibodies raised against purified ERV41 protein. For tagged versions, anti-tag antibodies (such as anti-HA for HA-tagged ERV41) provide high specificity and sensitivity .

The methodology typically involves:

• Protein extraction from cells using appropriate lysis buffers (e.g., 50 mM Tris-HCl, pH 9.0, 5% SDS, and 100 mM DTT for yeast cells)

• Separation of proteins by SDS-PAGE (typically on 14% polyacrylamide gels for optimal resolution of ERV41)

• Transfer to nitrocellulose or PVDF membranes

• Blocking and probing with primary antibodies specific for ERV41

• Detection using chemiluminescence or fluorescence-based secondary antibodies

When analyzing membrane fractions or vesicle preparations, it's crucial to include appropriate controls such as Sec61 (negative control for COPII vesicles) and Coy1 (positive control for COPII vesicles) .

How can in vitro vesicle budding assays be optimized to study ERV41 trafficking?

In vitro vesicle budding assays are powerful tools for studying ERV41 trafficking through the early secretory pathway. To optimize these assays specifically for ERV41 studies, the following methodological considerations are important:

• Preparation of semi-intact cells (SICs): Use washed SICs from strains expressing either wild-type or mutant versions of ERV41. For comparative studies, use isogenic strains where the endogenous ERV41 has been deleted (erv41Δ) and replaced with plasmid-expressed variants .

• COPII reconstitution components: Include purified COPII proteins (Sar1, Sec23-Sec24, and Sec13-Sec31), GTP, and an ATP regeneration system. Incubate reactions at 25°C for 30 minutes to allow vesicle formation .

• Vesicle isolation: Pellet the SICs at 24,104 g for 3 minutes at 4°C, then recover vesicles from the supernatant by ultracentrifugation at 100,000 g .

• Controls and quantification: Always include reactions without COPII proteins as negative controls. Use 10% of the total reaction as a loading control to calculate packaging efficiency. Include marker proteins like Sec61 (negative control) and Coy1 (positive control) to validate vesicle preparation quality .

• Quantification: For accurate assessment of packaging efficiency, quantify the intensity of ERV41 bands in both the total sample and vesicle fractions using image analysis software. Calculate the ratio of ERV41 in vesicles relative to 10% of total input to determine packaging efficiency .

This optimized protocol allows for reliable quantitative assessment of wild-type and mutant ERV41 incorporation into COPII vesicles, facilitating the identification of trafficking signals and interaction partners.

What quantitative proteomics approaches are most effective for identifying ERV41-dependent cargo proteins?

SILAC-based quantitative proteomics has proven highly effective for identifying ERV41-dependent cargo proteins by comparing protein abundance in wild-type and erv41Δ strains. The methodology involves:

• Cell labeling: Grow wild-type strains in media containing light amino acids and erv41Δ strains in media containing heavy isotope-labeled amino acids (typically lysine and arginine) at 30°C .

• Sample preparation: Mix equal amounts (e.g., 40 OD₆₀₀ units) of light-labeled control and heavy-labeled mutant cells before cell lysis. Lyse cells in buffer containing 50 mM Tris-HCl, pH 9.0, 5% SDS, and 100 mM DTT at 55°C for 30 minutes .

• Protein digestion: Dilute lysates with 8 M urea and 0.1 M Tris-HCl (pH 8.5) to reduce SDS concentration to 0.5%. Digest proteins using the filter-aided sample preparation (FASP) method with endoproteinase LysC .

• LC-MS/MS analysis: Perform reversed-phase chromatography using a liquid chromatograph system connected to a high-resolution mass spectrometer (e.g., Q Exactive) through nano-electrospray ionization. Acquire data in data-dependent mode to switch between full scan mass spectrometry and up to 10 data-dependent tandem mass spectrometry scans .

• Data analysis: Analyze the resulting MS and MS/MS spectra using software like MaxQuant with its integrated Andromeda search algorithms. Perform triplicate LC-MS runs for independent biological duplicates to ensure reproducibility .

• Identification of significant changes: Focus on proteins that show consistent reduction (e.g., log₂ ratio < -0.4) in the erv41Δ strain compared to wild-type. Validate top candidates using independent methods such as immunoblotting of TAP-tagged proteins .

This approach identified approximately 20 proteins significantly reduced in both erv41Δ and erv46Δ strains from a total of nearly 3,500 quantified proteins, highlighting its power for discovering ERV41-dependent cargoes .

How should researchers interpret contradictory results between proteomics and immunoblotting when studying ERV41-dependent cargo?

When faced with contradictory results between proteomics and immunoblotting in ERV41 research, careful analytical approaches are required. This scenario is not uncommon, as observed in studies where some candidate cargo proteins identified by proteomics showed variable degrees of dependence on ERV41 when validated by immunoblotting .

To properly interpret such contradictions:

What statistical analyses are most appropriate for quantifying ERV41 packaging efficiency in COPII vesicles?

For quantifying ERV41 packaging efficiency in COPII vesicles, several statistical approaches are recommended:

This statistical framework allows for robust quantification of packaging efficiency differences between wild-type and mutant ERV41 proteins, enabling clear identification of residues critical for COPII vesicle incorporation .

How can researchers differentiate between direct and indirect effects of ERV41 deletion on protein abundance?

Differentiating between direct and indirect effects of ERV41 deletion on protein abundance requires a systematic experimental approach:

• Combined genetic approaches: Create double knockout strains (e.g., erv41Δ pep4Δ) to block vacuolar degradation of mislocalized proteins. If a protein's levels are restored in the double mutant, this suggests the protein is directly mislocalized to the vacuole in erv41Δ single mutants rather than affected by secondary mechanisms .

• Secretion analysis: Examine culture media for secreted proteins. Direct cargo of the ERV41-ERV46 complex will likely be secreted in erv41Δ strains, as seen with Fpr2 and Gls1. Proteins affected indirectly may not show this pattern .

• Localization studies: Use fluorescence microscopy or subcellular fractionation to track protein localization. Direct cargo will show altered localization patterns in erv41Δ strains, while indirectly affected proteins may retain normal localization but show reduced abundance.

• In vitro binding assays: Test direct physical interaction between the ERV41-ERV46 complex and candidate cargo proteins using purified components. This provides strong evidence for direct versus indirect relationships.

• Time-course analyses: Examine the temporal relationship between protein abundance changes. Immediate effects following ERV41 depletion suggest direct relationships, while delayed effects indicate secondary consequences.

• Recovery experiments: Test whether reintroduction of ERV41 restores normal levels of affected proteins. Direct cargo should show rapid recovery, while proteins affected through complex cellular adaptations may respond more slowly.

By integrating these approaches, researchers can confidently classify proteins as direct cargo of the ERV41-ERV46 complex versus those affected through indirect cellular consequences of ERV41 deletion .

What are common issues in detecting ERV41 by immunoblotting and how can they be resolved?

Researchers often encounter several challenges when attempting to detect ERV41 by immunoblotting. Here are common issues and their solutions:

• Weak or absent signal:

  • Cause: Insufficient protein extraction from membrane fractions or low antibody sensitivity

  • Solution: Use stronger extraction buffers containing detergents (5% SDS) and reducing agents (100 mM DTT), and heat samples at 55°C for 30 minutes to solubilize membrane proteins effectively . Consider using an enhanced chemiluminescence system with longer exposure times.

• Multiple or non-specific bands:

  • Cause: Cross-reactivity of antibodies or protein degradation

  • Solution: Include appropriate controls (erv41Δ strain lysate as negative control). Use freshly prepared samples with protease inhibitors to prevent degradation. Consider using epitope-tagged versions of ERV41 if antibody specificity is problematic .

• Inconsistent loading controls:

  • Cause: Variable extraction efficiency of membrane proteins

  • Solution: Normalize to stable membrane proteins from the same compartment (e.g., Sec61 for ER membrane proteins) rather than cytosolic proteins or total protein stains .

• Variable results between experiments:

  • Cause: Differences in growth conditions or extraction efficiency

  • Solution: Standardize growth conditions (temperature, media, harvest OD) and extraction procedures. Include internal reference samples across blots for inter-experimental normalization.

• Difficulty detecting ERV41 in vesicle fractions:

  • Cause: Low concentration of vesicles or inefficient recovery

  • Solution: Optimize ultracentrifugation parameters (100,000 g is recommended) and ensure careful handling of the vesicle pellet. Consider using more sensitive detection methods such as fluorescent secondary antibodies .

By addressing these common issues, researchers can achieve more consistent and reliable detection of ERV41 in various experimental contexts.

How can researchers troubleshoot unsuccessful ERV41 mutagenesis experiments?

When encountering difficulties with ERV41 mutagenesis experiments, systematic troubleshooting can identify and resolve the underlying issues:

• Verification of mutagenesis success:

  • Problem: Uncertainty about whether the desired mutation was introduced

  • Solution: Sequence the entire coding region of ERV41 to confirm the presence of the intended mutation and absence of unwanted mutations. For point mutations affecting C-terminal sorting signals (e.g., I349A, L350A), verification is particularly important as these residues are critical for function .

• Expression level issues:

  • Problem: Mutant ERV41 expressed at much lower levels than wild-type

  • Solution: Check protein stability by cycloheximide chase experiments. If the mutant is unstable, consider creating an ERV41 variant with multiple mutations or using a stronger promoter to increase expression levels. Compare expression to wild-type ERV41 expressed from the same vector to control for plasmid-based expression differences .

• Complex formation disruption:

  • Problem: Mutations in ERV41 disrupt complex formation with ERV46

  • Solution: Perform co-immunoprecipitation experiments to assess complex formation efficiency. Some mutations may specifically affect trafficking while preserving complex formation (e.g., C-terminal mutations), while others may disrupt the complex itself, complicating interpretation .

• Phenotypic assessment challenges:

  • Problem: Difficulty in detecting phenotypic effects of mutations

  • Solution: Use multiple readouts including subcellular localization of ERV41, packaging into COPII vesicles, and ability to prevent mislocalization of cargo proteins. The most sensitive assay appears to be the in vitro budding assay, which can detect subtle defects in trafficking signals .

• Plasmid-based expression artifacts:

  • Problem: Behavior of plasmid-expressed ERV41 differs from endogenous protein

  • Solution: Consider genomic integration of mutant constructs to ensure physiological expression levels. Alternatively, use CEN-based low-copy plasmids rather than high-copy vectors to approximate endogenous expression levels .

By systematically addressing these potential issues, researchers can improve the success rate and interpretability of ERV41 mutagenesis experiments.

What strategies can resolve poor reproducibility in quantitative proteomics studies of ERV41-dependent cargo?

Poor reproducibility in quantitative proteomics studies of ERV41-dependent cargo can undermine research findings. To address this challenge, implement these strategies:

• Standardize growth conditions:

  • Ensure consistent culture medium composition, growth temperature (30°C), and harvest at identical optical density

  • For SILAC experiments, verify complete incorporation of heavy amino acids by analyzing test samples before the main experiment

• Optimize sample preparation:

  • Use standardized lysis buffers (50 mM Tris-HCl, pH 9.0, 5% SDS, 100 mM DTT) and consistent lysis conditions (30 min at 55°C)

  • Clear lysates by centrifugation at standardized speed (17,000 g for 10 min)

  • Implement strict quality control for protein quantification before mixing samples

• Control sample mixing:

  • Mix precisely equal amounts (e.g., 40 OD₆₀₀ units) of light-labeled control and heavy-labeled mutant cells before processing

  • Verify mixing ratios by analyzing housekeeping proteins that should show no change between conditions

• Improve peptide preparation and separation:

  • Use filter-aided sample preparation (FASP) with standardized protocols

  • Ensure consistent desalting procedures before LC-MS/MS analysis

  • Implement identical chromatographic conditions across runs (same column, gradient, flow rate)

• Implement robust experimental design:

  • Perform triplicate LC-MS runs for each of at least duplicate biological samples

  • Include label-swapping experiments to control for potential bias in labeling efficiency

  • Consider spike-in standards of known concentration to normalize across experiments

• Apply appropriate statistical analysis:

  • Use statistical tools designed for proteomics data (e.g., Perseus software)

  • Apply appropriate normalization methods to correct for technical variation

  • Establish clear significance thresholds (e.g., log₂ ratio < -0.4) based on the distribution of the entire dataset

• Validate with orthogonal methods:

  • Confirm key findings using techniques like immunoblotting of TAP-tagged proteins

  • Analyze multiple independently prepared samples to ensure biological reproducibility

What are promising approaches for identifying the cargo recognition motif in ERV41-ERV46 dependent proteins?

Identifying the specific cargo recognition motif in proteins dependent on the ERV41-ERV46 complex represents a significant research opportunity. Several methodological approaches show promise:

• Structure-guided mutagenesis: The ERV41 luminal domain has a distinctive β-sandwich arrangement with a prominent negative electrostatic surface patch. This structural feature likely mediates cargo binding . Creating targeted mutations in this region and assessing binding to model cargo proteins like Fpr2 could help define the binding interface.

• Systematic mutation of cargo proteins: Using the compact Fpr2 (118 amino acids) as a model cargo, create systematic alanine scanning or deletion mutants to identify regions critical for ERV41-ERV46-dependent trafficking. This approach has been successfully applied to other retrieval signals and could identify a minimal motif sequence .

• Cross-linking coupled with mass spectrometry: Apply in vivo or in vitro cross-linking between purified ERV41-ERV46 complex and cargo proteins, followed by mass spectrometry analysis to map interaction sites with amino acid-level resolution.

• Comparative sequence analysis: Perform bioinformatic analysis of the currently identified ERV41-ERV46 cargo proteins (Gls1, Fpr2, Jem1, Vps62) to identify common sequence or structural elements that might serve as recognition signals .

• Peptide library screening: Develop peptide libraries based on sequences from known cargo proteins and screen for binding to the purified luminal domain of ERV41. This could identify minimal peptide motifs sufficient for recognition.

• Cryo-EM structural studies: Determine the structure of the ERV41-ERV46 complex bound to cargo proteins to provide direct visualization of the interaction interface and recognition mechanism.

These approaches, especially when used in combination, have significant potential to identify the specific recognition motif used by the ERV41-ERV46 complex, which would enable prediction of additional cargo proteins and potentially reveal parallels to host-pathogen interactions involving ER targeting .

How might the ERV41-ERV46 retrieval system be implicated in human disease processes?

The ERV41-ERV46 retrieval system's potential involvement in human disease processes represents an important frontier for translational research. Several hypotheses warrant investigation:

• Neurodegenerative diseases: Many neurodegenerative disorders involve protein misfolding and ER stress. Given that the ERV41-ERV46 complex retrieves ER folding machinery components like Gls1 (glucosidase I) and Fpr2 (prolyl-isomerase), dysfunction in this retrieval system could potentially contribute to conditions like Alzheimer's disease or Parkinson's disease by disrupting ER protein quality control .

• Host-pathogen interactions: The observation that certain microbes express KDEL-bearing pathogenic factors to gain access to the ER suggests that analogous mechanisms might exist for targeting the ERV41-ERV46 pathway. Identification of the ERV41-ERV46 recognition motif could reveal whether similar strategies are employed by pathogens to exploit this trafficking route .

• Congenital disorders of glycosylation: Since Gls1 (glucosidase I) is a key ERV41-ERV46 cargo involved in N-glycan processing, defects in its proper localization could potentially contribute to glycosylation disorders. Investigating whether ERV41-ERV46 dysfunction contributes to unexplained cases of congenital disorders of glycosylation would be valuable.

• ER storage diseases: These conditions result from accumulation of misfolded proteins in the ER. If ERV41-ERV46 dysfunction leads to depletion of ER-resident chaperones and folding enzymes, it could potentially exacerbate such conditions by reducing the cell's capacity to handle protein folding challenges.

• Cancer cell metabolism: Cancer cells often upregulate protein synthesis and face elevated ER stress. The ERV41-ERV46 system may play a role in helping cancer cells maintain ER homeostasis under these conditions, potentially offering a novel therapeutic target.

Methodologically, these hypotheses could be investigated through studies of patient-derived cells, mouse models with targeted mutations in ERV41 or ERV46 orthologs, and analysis of ERV41-ERV46 expression patterns in disease tissues. The high conservation of these proteins across species suggests that findings in model organisms like yeast are likely relevant to human health and disease .

What technological advances could enhance the study of ERV41-dependent trafficking processes?

Several emerging technologies and methodological advances show promise for enhancing our understanding of ERV41-dependent trafficking processes:

• Live-cell imaging with improved spatiotemporal resolution: Developing advanced imaging techniques using split-fluorescent protein tags or environmentally sensitive fluorophores could allow real-time visualization of ERV41-ERV46 complex trafficking between the ER and Golgi. This would provide insights into the dynamics of cargo capture and release that are difficult to obtain with traditional biochemical approaches.

• Proximity labeling proteomics: Techniques such as BioID or APEX2 could be applied by fusing these enzymes to ERV41 or ERV46, allowing the labeling of proteins in close proximity during trafficking events. This approach could identify transient interactions with both cargo proteins and trafficking machinery components under physiological conditions .

• Microfluidic organelle isolation: Developing methods to rapidly isolate pure populations of transport vesicles containing the ERV41-ERV46 complex would enable more precise characterization of their protein and lipid composition.

• Cryo-electron tomography: This technique could provide structural insights into the organization of the ERV41-ERV46 complex within native membrane environments of transport vesicles, offering a more physiological view than reconstituted systems.

• Genome-wide CRISPR screens: Applying CRISPR-based functional genomics to identify genes that modify ERV41-ERV46 trafficking phenotypes could reveal new components of this pathway. This approach could be particularly powerful when combined with fluorescent reporters for ERV41-dependent cargo localization.

• Organoid systems: Developing organoid systems that recapitulate the early secretory pathway in a more physiological context would allow study of ERV41-ERV46 function in complex tissue-like environments rather than simple cell culture systems.

• In silico modeling: As computational power increases, molecular dynamics simulations could model interactions between the ERV41-ERV46 complex and its cargo proteins, potentially predicting recognition motifs and guiding experimental design.

These technological advances would complement existing approaches like quantitative proteomics and in vitro vesicle budding assays , providing a more comprehensive understanding of ERV41-dependent trafficking processes and potentially revealing new therapeutic opportunities.